Black Diamond Therapeutics, Inc. — Q2 2023 Form 10-Q
Business context and reporting period. Black Diamond is a clinical-stage precision oncology company developing mutation-targeted therapies using its MAP drug discovery platform. This unaudited report covers the quarter and six months ended June 30, 2023. The company has no approved products and has generated no product revenue.
Financial performance and position
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $13.2m | $16.2m | $27.9m | $34.0m |
| General and administrative expense | $6.9m | $7.0m | $13.7m | $14.9m |
| Total operating expenses / operating loss | $20.0m | $23.2m | $41.6m | $48.9m |
| Net loss | $19.2m | $22.9m | $40.0m | $48.4m |
| Basic and diluted loss per share | $0.52 | $0.63 | $1.09 | $1.33 |
| Cash used in operating activities | — | — | $34.4m | $46.7m |
At June 30, 2023, cash and cash equivalents were $41.9m and investments were $47.6m, totaling $89.5m. Total assets were $119.9m; total liabilities were $37.7m, including $26.8m of operating lease liabilities. The filing reports no borrowings or other financial debt. The company had an accumulated deficit of $375.0m. Profit margins are not meaningful because the company had no revenue.
Operating cash use improved year over year. Investing activities provided $42.0m in the first half of 2023, primarily from investment sales and maturities; financing activities provided $0.1m. These investment proceeds are not operating cash generation.
Material changes versus prior comparable periods
- Q2 net loss narrowed by $3.8m, and first-half net loss narrowed by $8.4m year over year, reflecting lower operating expenses and higher other income.
- First-half R&D expense declined $6.1m. Lower spending on discontinued BDTX-189, early discovery/platform work, and personnel offset increased clinical-trial spending for BDTX-1535 and BDTX-4933.
- On July 5, 2023, after quarter-end, the company sold 15.0m common shares at $5.00 per share, receiving approximately $71.6m net. The overallotment option expired unexercised. Shares outstanding were 51,575,323 as of August 1, 2023.
Outlook, developments, and risks
- Liquidity outlook: Management estimated that June 30 cash, cash equivalents and investments, together with the July offering proceeds, would fund planned operating and capital requirements into the first half of 2025. This estimate depends on assumptions and capital could be exhausted sooner; additional financing will likely be needed.
- BDTX-1535: June dose-escalation results showed confirmed partial responses in 5 of 12 evaluable NSCLC patients in a subgroup, one additional unconfirmed response, and stable disease in the remaining six. Management described tolerability as generally favorable, with no dose-limiting toxicities at 15–200 mg once daily; dose-limiting toxicities occurred in 1 of 15 patients at 300 mg and 5 of 12 at 400 mg. NSCLC expansion cohorts began in July; a GBM dose-escalation update was expected in Q4 2023.
- BDTX-4933: A Phase 1 trial for selected patients with BRAF or RAS mutations began in Q2 2023.
- Pipeline focus: BDTX-4876 was selected as an FGFR development candidate; the company plans to evaluate strategic alternatives for it. Another undisclosed solid-tumor program was expected to advance to candidate nomination in 2023. BDTX-189 development was discontinued.
- Key risks: Continued losses, clinical and regulatory uncertainty, competition, and dependence on future financing or partnerships. Equity financing may dilute shareholders; other financing or collaboration terms could restrict operations or require relinquishing rights. The company noted banking-sector instability as a risk, but reported no material SVB deposits or adverse liquidity impact as of the filing date.
- Potential license milestone and royalty payments are contingent and not reasonably estimable. The company reported no material legal proceedings and no material indemnification liabilities.
Important facts for investors to verify
- Whether BDTX-1535 response, safety, and expansion-cohort results support further development, including the planned GBM update.
- BDTX-4933 trial progress and future clinical milestones, and the outcome of strategic alternatives for BDTX-4876.
- Actual cash burn and whether the stated runway into the first half of 2025 remains achievable as trials advance.
- The impact of the July share issuance on dilution and the company’s ability to secure additional capital on acceptable terms.
- Future clinical, regulatory, manufacturing, licensing, and other contingent costs, which may differ materially from current estimates.